NASDAQ · KRYS
Healthcare · Biotechnology
$332.29
Up+$7.74 (+2.38%)
Updated Oct 31, 2026, 6:49 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · KRYS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
KRYS closed at $332.29 after 21 trading sessions, up 3.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $326.37 | $332.63 | $319.95 | $332.29 | 330.31K |
| Oct 29, 2026 | $323.77 | $326.98 | $319.43 | $324.55 | 190.77K |
| Oct 28, 2026 | $317.81 | $322.085 | $315.86 | $321.42 | 199.84K |
| Oct 27, 2026 | $311.52 | $321.015 | $311.52 | $320.58 | 212.81K |
| Oct 26, 2026 | $313.56 | $317.76 | $309.63 | $313.66 | 223.65K |
| Oct 23, 2026 | $318.91 | $318.91 | $310.5608 | $311.50 | 270.07K |
| Oct 22, 2026 | $320.44 | $328.48 | $317.05 | $320.13 | 245.21K |
| Oct 21, 2026 | $324.31 | $327.35 | $319.83 | $322.17 | 468.87K |
| Oct 20, 2026 | $321.80 | $328.7599 | $321.26 | $325.42 | 195.45K |
| Oct 19, 2026 | $320.30 | $321.65 | $314.22 | $320.25 | 207.7K |
| Oct 16, 2026 | $329.94 | $331.025 | $315.385 | $316.58 | 226.23K |
| Oct 15, 2026 | $332.98 | $338.91 | $328.511 | $330.00 | 288.02K |
| Oct 14, 2026 | $320.41 | $330.965 | $319.01 | $330.69 | 277.54K |
| Oct 13, 2026 | $331.48 | $331.93 | $320.95 | $321.16 | 281.91K |
| Oct 12, 2026 | $329.14 | $334.27 | $328.53 | $332.07 | 168.07K |
| Oct 9, 2026 | $326.55 | $333.56 | $323.87 | $331.61 | 196.96K |
| Oct 8, 2026 | $321.61 | $332.105 | $319.58 | $327.30 | 271.47K |
| Oct 7, 2026 | $324.87 | $330.44 | $320.195 | $324.57 | 354.15K |
| Oct 6, 2026 | $335.16 | $335.16 | $319.61 | $326.81 | 352.14K |
| Oct 5, 2026 | $323.76 | $339.69 | $321.365 | $334.85 | 337.05K |
| Oct 2, 2026 | $326.75 | $329.22 | $320.29 | $322.28 | 425.68K |
The latest Smart Investors Daily articles mentioning KRYS.
Company
Market Activity
Research & News
KRYS research
Company profile and research snapshot.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
| Sep 21, 2026 | B of A Securities | Buy | — |
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 22, 2026
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market capitalization of
Yahoo · Oct 22, 2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcas
Yahoo · Oct 15, 2026
Krystal Biotech, Inc. (NASDAQ:KRYS) reported preliminary clinical findings from a pilot study of KB113, an investigational intratumoral immunotherapy being developed for patients with Gorlin syndrome, showing regression in more than 80% of assessed basal cell carcinoma (BCC) lesions.
Benzinga · Oct 15, 2026
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KRYS.
